Caris Diagnostics Providing KRAS Mutational Analysis for Colon Cance...(n a patient's tumor. The Company current...),Health

Date:6/24/2008

n a patient's tumor. The Company currently receives, processes and provides medical opinions on over one thousand GI biopsies per day. Caris MPI developed the KRAS mutation analysis so that it can be performed on these same biopsies without any need for additional coordination, or delay, and with the highest quality standards.

"Given our leading position in gastrointestinal pathology, it is not only natural, but also imperative for us to offer our clinicians this critical information for their treatment decisions," concluded David D. Halbert, Chairman of Caris Dx. "We have been predicting the convergence of anatomic pathology and molecular testing for some time. With our ability to perform the KRAS analysis on the biopsies that we receive for initial cancer diagnosis each week, the paths of anatomic and molecular test are now united. We look forward to adding further analyses to our Target GI testing panel in the future."

Physicians who are seeking additional information for their patients when considering treatment with Erbitux and/or Vectibix can order mutation analysis for KRAS by contacting 1-800-901-5177.

About Caris Diagnostics

Caris Diagnostics (Caris Dx) is a leading provider of the highest quality diagnostic, translational development and pharmaceutical services encompassing anatomic pathology and molecular testing. Caris Diagnostics provides world- class pathology services to physicians who treat patients in the community setting. The company provides academic-caliber medical consults through its industry-leading team of subspecialty fellowship and expert-trained pathologists in gastrointestinal and liver pathology, dermatopathology and hematopathology. Caris Diagnostics provides the highest levels of service to its customers and their patients through its state-of-the art laboratories; proprietary, advanced clinical and technology solutions; and rigorous quality assurance programs. Through the molecular testing expertise of the
'/>"/>

SOURCE Caris Diagnostics Copyright©2008 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4
Related medicine news :

1. Caris Diagnostics Announces Addition of Leading Dermatopathologist to Expand Subspecialty Expertise
2. FDA Approves SOMA(R) (carisoprodol) 250 mg
3. Quest Diagnostics to Speak at the Jefferies 2nd Annual Healthcare Conference
4. Quest Diagnostics to Provide Diagnostic Testing Services for the Women of Ireland through Irelands First Nationwide Cervical-Cancer Screening Program
5. Escalon(R) Enhances Position Within IVD Reagent Market with Strategic Acquisition of JAS Diagnostics
6. Johnson & Johnson Reviews Growth Strategies for Medical Devices & Diagnostics and Consumer Businesses
7. Johnson & Johnson to Host Medical Devices & Diagnostics and Consumer Business Review
8. Quest Diagnostics Chooses Roches Fully Automated, Real-Time HIV-1 Viral Load Monitoring Test For Its Customers in Laboratories Nationwide
9. Quest Diagnostics Is Named Best Employer For Healthy Lifestyles
10. Quest Diagnostics Reports Strong Revenue and Earnings Growth in First Quarter 2008
11. Allegro Diagnostics Announces Publication in Cancer Prevention Research of Prediction Model for Lung Cancer Diagnosis Integrating Clinical and Genomic Features